Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509157 | 0.85 | NR4A2 (0.56) | KMT2ANR4A2SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4509754 | 0.85 | ALDH1A1 (0.60) | KMT2ANR4A2SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4500611 | 0.84 | KMT2A (0.50) | KMT2ANR4A2SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4509785 | 0.83 | SMN1; SMN2 (0.49) | KMT2ANR4A2SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL5487993 | 0.81 | NR4A2 (0.58) | KMT2ANR4A2SMN1; SMN2PLA2G4BMEN1 | |
| SCHEMBL1573343 | 0.81 | ALDH1A1 (0.55) | KMT2ANR4A2SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL1573336 | 0.81 | KMT2A (0.57) | KMT2ANR4A2SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL21217871 | 0.79 | HSD17B10 (0.56) | KMT2ANR4A2SMN1; SMN2ALDH1A1PLA2G4B | |
| SCHEMBL9741522 | 0.77 | NR4A2 (0.61) | KMT2ANR4A2PLA2G4BNPC1RAB9A | |
| SCHEMBL10167730 | 0.77 | NR4A2 (0.65) | KMT2ANR4A2HTTPLA2G4BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | PRMT5 2891/4885WDR77 2831/4885KMT2A 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.